John Wilkerson is a Washington correspondent for STAT who writes about the politics of health care. He is also the author of the twice-weekly D.C. Diagnosis newsletter. Emory is the data editor at ...
We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...
Prefilled drug delivery device specialist Apiject has signed a lease for a new site in Apex, North Carolina, that will house two blow-fill-seal production lines. The 30,000-square-foot facility will ...
The Hatch-Waxman Act has always represented a delicate balance between the interests of innovator and generic drugmakers: innovators seek to maintain exclusivity as broadly and long as possible, ...
OpenJDK project teams will focus work on features such as value types, code reflection, AOT compilation, and structured concurrency in the coming year. Oracle’s Java team in 2026 will work toward ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A lawsuit claims that Teva and ...
Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Cory Benfield discusses the evolution of ...
Cuban urges FDA fee waiver to boost US generics manufacturing Cost Plus Drugs plans to boost US production if fees are waived FDA charges $360,000 per generic drug approval application Trump promised ...
Monday - Friday, 11:00 - 12:00 SIN/HK | 0500 - 06:00 CET Shreehas Tambe, CEO & managing director of Biocon Biologics, discusses the way that US tariff & manufacturing policy affects India's ...
Dolby unveiled Dolby Vision 2 in September, and Samsung has already fired back with its own upgrades to its image quality format. The company is a key player in the consortium behind the HDR10 and ...
The Food and Drug Administration (FDA) is launching an effort to streamline the approval process for cheaper alternative “biosimilar” versions of biologic drugs as a way to curb health costs. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results